Health ❯ Healthcare ❯ Research Studies

Phase 3 Trials

Efficacy and Safety ESSENCE Trial SURMOUNT-5 Study Efficacy Comparisons IGNYTE-3 Trial ASCENT-07 Study

Sacituzumab Govitecan Gains First-Line Ground in TNBC, Falls Short in Early HR+/HER2− Use

SABCS presentations underscore subtype‑specific use requiring careful treatment sequencing.

Replimune Reports No Defined Accelerated-Approval Path After FDA Type A Meeting on RP1 for Melanoma